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Abstract
Fabry disease is an X-linked genetic deficiency in the alpha-galactosidase
enzyme resulting in intracellular accumulation of glycosphingolipids and
multisystem organ dysfunction. Typically 50% of males and 20% of affected
females have renal involvement, ranging from proteinuria or reduced renal
function, renal parapelvic cysts and progressive renal disease ultimately
requiring transplantation or dialysis. The phenotypic presentation of Fabry
disease is incredibly varied and will even vary between family members with
the same confirmed genetic mutation. In a cohort of patients affected by Fabry
disease in the North East of England we examine the different phenotypic
presentations of eight index cases (6 male, 2 female) with predominantly renal
disease and the renal manifestations within their family members. The mean
age of presentation was 40 years of age (range 23-59 years). Various
multisystem manifestations were observed including cardiac, neurological,
cerebrovascular and skin involvement. Two of the male index patients reached
end stage renal disease (ESRD) requiring renal replacement therapy. Two
female index patients had phenotypes limited to hypertension and proteinuria
at presentation and the remaining patients had either stable or progressive
chronic kidney disease at the time of diagnosis. We demonstrate the need for a
high index of suspicion in order to consider Fabry disease as a diagnosis and
the importance of cascade genetic screening to identify affected family
members so that treatment can be initiated in a timely fashion.
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Introduction
Fabry disease (also called Anderson-Fabry disease) is an 
X-linked genetic deficiency in the alpha-galactosidase enzyme 
resulting in an intracellular accumulation of globotriaosylceramide 
(Gb3) and related glycosphingolipids causing organ dysfunction1. 
Classic manifestations include acroparesthesia (burning/tingling/
numbness at extremities), angiokeratoma (typically over the bath-
ing suit area but can be focal or diffuse) and corneal lipid accumu-
lation known as cornea verticillata or Fleischer vortex dystrophy 
(seen on slit-lamp examination)2. The condition can also result 
in progressive renal impairment, gastrointestinal symptoms, heart 
disease and neurological involvement, including early stroke.
Symptoms of Fabry disease can present in early childhood with 
overt organ dysfunction usually apparent by the second or third 
decade, however the phenotype is often variable even within 
single families3. Furthermore, female heterozygotes often have 
a degree of alpha-galactosidase activity present resulting in later 
onset of milder symptoms. Similarly, male patients with atypi-
cal variants due to preserved low levels of alpha-galactosidase 
may present later, typically in the third or fourth decade2.
It is partly this wide variation in clinical presentation that often 
leads to a delay in diagnosis. Fabry disease remains a rare disease 
and a high index of clinical suspicion is required to make a new 
diagnosis. However, with the advent of enzymatic and genetic 
screening more patients are being identified through a process of 
cascade screening allowing earlier initiation of treatment. Each 
index case diagnosed will typically lead to 3–4 cases on cascade 
screening4. Study data suggests that enzyme replacement therapy 
(ERT) may slow progression of renal dysfunction if instituted early 
however it is of less benefit when patients already have significantly 
reduced renal function and proteinuria5–7.
As many as 50% males and 20% of females with Fabry disease 
have renal manifestations2. Proteinuria and reduced estimated 
glomerular filtration rate (eGFR) may be present in early 
childhood8. If a renal biopsy is undertaken the pathognomonic 
histological renal lesion on electron microscopy is that of myelin-
like inclusions known as “zebra bodies”. These can be seen in the 
lysosomes of cells predominantly within the glomerular and dis-
tal tubule due to Gb3 deposition. As the kidney disease progresses 
podocytes and endothelial cells become hypertrophic with 
foamy appearing vacuoles. Glomerular mesangial thickening then 
occurs leading to focal and then global glomerulosclerosis which 
can be detected under light microscopy9. Urinary epithelial cells 
may also have a vacuolated appearance containing a number of 
glycosphingolipids droplets and are then known as oval fat bodies.
A number of small studies and population data have demonstrated 
an increased prevalence of parapelvic and renal sinus cysts in 
patients with Fabry disease10. The prevalence of cysts increases 
with age not unlike the prevalence of simple cysts within the 
general population. The exact aetiology of parapelvic cysts in 
Fabry disease is unknown. However the specific finding of renal 
sinus or parapelvic cysts on imaging in a young adult with 
renal impairment should raise the possibility of the disease as a 
diagnosis11. Parapelvic cysts resemble renal cortical cysts in 
morphology but plunge into the renal sinus from the adjacent 
parenchyma. If large enough they may compress the pelvicalyceal 
system causing hydronephrosis but due to their hypoechogenicity 
they may actually be mistaken for hydronephrosis on ultrasound 
imaging12.
Preferential involvement of the distal tubules relative to other 
segments results in a reduced ability to concentrate urine, mean-
ing polyuria may be the first manifestation of renal involvement13. 
However, it is usually the development of proteinuria or renal 
impairment that initiates referral to renal services / nephrology 
departments. Proteinuria and renal impairment progress with 
advancing age and result in end stage renal disease (ESRD) in 
almost all male patients and a significant proportion of female 
patients, if untreated. ESRD is the leading cause of death in male 
patients with untreated Fabry disease14. Heavy proteinuria is 
more common in adult males and is associated with a more 
rapid deterioration in renal function15. Although proteinuria 
is strongly associated with disease progression, it is not always 
overt in advanced renal disease.
Treatment of Fabry disease consists of providing patients with 
recombinant human alpha-galactosidase. Two formulations cur-
rently exist and appear to be equally efficacious however both have 
a significant treatment cost. Some clinicians choose to treat clas-
sically presenting males (with low or absent alpha-galactosidase 
levels) as soon as the diagnosis is established in order to prevent 
disease progression. Due to the limited evidence of benefits of ERT 
in patients with established renal impairment, the European Best 
Practice Group do not advocate treatment in patients who already 
have established renal impairment (eGFR<60mL/min/1.73m2 
or proteinuria>1g/day) unless they have non-renal symp-
toms that require treatment. A new chaperone therapy called 
migalastat is able to bind and stabilise certain mutant enzymes, 
allowing their proper trafficking to the lysosomes where they are 
able to function. Migalastat offers an alternative treatment option 
where ERT has lost efficacy, for example in cases of antibody 
formation to ERT. It also has the advantage of being an orally 
administered drug and has recently been recommended by NICE 
(see NICE recommendation for Migalastat). However, the longer-
term benefits of this drug are not known. A recent 6 month 
placebo controlled study of this drug provided disappointing 
results with no difference in response between drug and placebo16, 
whilst an 18 month randomised study comparing ERT and 
open label migalastat produced more encouraging results17.
As with other forms of proteinuric chronic kidney disease (CKD), 
hypertension should be treated to a target of below 130/80 mmHg. 
It is reasonable to treat with an Angiotensin-Converting Enzyme 
inhibitor or Angiotensin Receptor Blockers as anti-proteinuric 
agents18. Complications of CKD such as anaemia and renal 
bone disease should be managed in the same way as for other 
forms of CKD and ultimately patients should be offered dialysis or 
transplantation if required.
Patients with Fabry disease have an increased mortality on 
dialysis when compared to other (non-diabetic) causes of ESRD 
and the condition is associated with a reduced quality of life on 
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dialysis compared to other patient groups19. Transplantation is 
therefore recommended as first line treatment for patients with 
ESRD due to Fabry nephropathy. Post transplantation examina-
tion of kidney allograft tissue can show Fabry inclusion bod-
ies however they do not appear to cause graft dysfunction20. 
Dialysis patients with Fabry disease and transplant recipients may 
still derive benefit from ERT for extra-renal manifestations such 
as neurological and cardiac disease.
Within the North East of England there is a sizeable cohort of 
patients with Fabry disease. Here we review the varying pheno-
typic presentations of eight patients with overt renal disease and 
the renal manifestations of Fabry disease within their families 
(Table 1). These summaries hopefully help to emphasise the pre-
senting features and patterns of disease progression where the 
proband has renal features. The importance of a full family history 
cannot be understated (Figure 1), as well as looking for evidence 
of male to male transmission of disease, which would exclude 
X-linked inherited disease
Family A
37 year old male was referred to nephrology following the 
detection of skin lesions that were identified as angiok-
eratoma. He was noted to have reduced serum alpha- 
galactosidase levels. At the time his blood pressure and renal 
function were documented as normal (serum creatinine within 
reference range) with no evidence of proteinuria. Within 3 years 
his kidney function deteriorated and he unfortunately progressed 
to ESRD, requiring haemodialysis. He was also was noted to 
have a mild hypertrophic cardiomyopathy.
Separately, his older brother, aged 47 years, was also noted 
to have skin lesions, having previously had an ischaemic stroke 
at the age of 46. A diagnosis of Fabry disease was confirmed 
by reduced serum alpha galactosidase levels. He also was docu-
mented as having normal renal function (serum creatinine within 
reference range) and left ventricular hypertrophy (LVH). He 
was treated with ERT. Over the last decade there has been only 
a small decline in his renal function (eGFR 67 to 52 mL/min/1.73m2) 
with no evidence of proteinuria.
Mutation analysis in the proband and his brother confirmed 
a pathogenic GLA mutation p.Thr412Serfs and cascade screen-
ing has allowed the offspring of the two brothers to be genetically 
tested. A daughter and a grandson were identified as inheriting 
this pathogenic allele but are currently asymptomatic. Interest-
ingly, the brothers had a maternal aunt who was noted to have 
undergone renal transplantation for an unknown cause of 
ESRD. There was no other family history of renal disease.
Family B
A 39 year old lady with no family history of Fabry disease 
presented to Renal Services with hypertension, proteinuria but pre-
served renal function. A renal biopsy demonstrated multiple myelin 
inclusion bodies, typical of Fabry disease. Genetic tests confirmed 
a diagnosis of Fabry disease(GLA c.999-1G>C) and allowed test-
ing of her son and her sister, who were mutation negative. She 
commenced ERT approximately 1 year after presentation, and 
responded with a reduction in proteinuria. Her renal function has 
remained normal throughout (eGFR>90 mL/min/1.73m2).
Family C
A 38 year old man presented with proteinuria (Urine Protein 
Creatinine Ratio (UPCR) 56 µmol/mmol creatinine), preserved 
renal function (estimated Glomerular Fitration Rate (eGFR) 
79 mL/min/1.73m2) and a finding of possible renal cysts on ultra-
sound. He was also found to have a dilated left ventricle and aortic 
root on echocardiography. MR imaging of his kidneys demonstrated 
that his renal cysts were parapelvic in origin (Figure 2), pointing 
to a diagnosis of Fabry disease. He underwent subsequent genetic 
testing which confirmed a GLA splicing mutation and commenced 
on ERT within a year of his presentation. He has no contactable 
family members. His renal impairment progressed despite treat-
ment, reaching ESRD 10 years later at which point he received a 
pre-emptive live donor transplant.
Family D
A 50 year old male was diagnosed with Fabry disease following 
presentation to neurology services with gait disturbance and thigh 
pain. Brain MRI revealed a previous ischaemic stroke. At the time 
of diagnosis he had evidence of CKD (eGFR 82 mL/min/1.73m2) 
and proteinuria with macroscopically normal kidneys on ultra-
sound. He was also noted to have hypertrophic cardiomyopathy. 
He was commenced on enzyme replacement therapy. His renal 
function has declined since diagnosis 9 years ago and eGFR is 
now 43 mL/min/1.73m2 with significant proteinuria (UPCR 
108 µmol/mmol creatinine).
A year later his brother was referred to Renal Services 
aged 43 years with progressive renal dysfunction (estimated 
Glomerular Filtration Rate (eGFR) 57 mL/min/1.73m2) and pro-
teinuria. He had been made aware that his brother had a diag-
nosis of Fabry disease and his diagnosis was confirmed by low 
serum levels of alpha-galactosidase and genetic testing (missense 
mutation in GLA p.Ile117Ser). He was established on ERT but 
his renal function deteriorated over the last 10 years to an eGFR 
of 23 mL/min/1.73m2. He is currently being worked up for 
a pre-emptive renal transplant. He is otherwise asymptomatic.
Cascade screening in this family revealed that some of the 
brothers’ relatives were also affected, including a male mater-
nal cousin who had presented at 20 years of age with progres-
sive CKD resulting in ESRD. His originally documented cause of 
ESRD was of unknown aetiology. He subsequently underwent 
genetic testing which confirmed the same GLA mutation 
(p.Ile117Ser) as his cousins.
This large family had a number of other relatives who have pre-
sented to Renal Services or have been diagnosed as a result of 
cascade screening, including a 32 year old male cousin (also 
on the maternal side) who presented late with ESRD. He had been 
made aware of the diagnosis of Fabry disease within the family 
and his diagnosis was confirmed on renal biopsy and by genetic 
testing. He is now established on haemodialysis and receives ERT. 
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Figure 2. Parapelvic cysts in Fabry disease. MRI scan of proband from family C demonstrating bilateral parapelvic cysts.
Figure 1. Family pedigree diagrams. Males are represented by squares, females by circles. Affected males are coloured 
black. Carrier and affected females are marked with a dot. The proband for each family is marked with an arrow.
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His 39 year old brother was also diagnosed with Fabry disease the 
following year and was commenced on ERT. He reported clas-
sic neurological symptoms of acroparathesia and gastrointestinal 
upset and had normal renal function and only microalbuminuria 
at presentation. Both brothers have young daughters who have 
mild neurological symptoms that may be attributed to Fabry 
disease however they have normal renal function and have not 
yet undergone genetic testing.
Family E
A 59 year old man presented with severe hypertension that was 
refractory to anti-hypertensive therapy and he was referred to 
Renal Services for consideration of atypical causes. It came to 
light that his older brother had presented to Renal Services within 
the same centre 35 years before, aged 25 with severe hyperten-
sion and CKD. The older brother had rapidly progressed to ESRD 
within 3 years and was maintained on haemodialysis until 
he received a renal transplant aged 30 years. A review of the 
histological specimens taken at the time of a bilateral nephrec-
tomy aged 34 (performed for severe hypertension) confirmed the 
presence of myelin inclusion bodies (zebra bodies) on electron 
microscopy.
A younger brother had undergone investigations over the years for 
a variety of symptoms and was also noted to have LVH, normal 
renal function but had documented microalbuminuria. The 3 broth-
ers were found to have low levels of alpha-galactosidase activity 
and genetic analysis confirmed that all three siblings shared the 
identical p.Arg301Gln missense mutation. This degree of 
phenotypic variation within a family with the same genetic muta-
tion is unusual and could potentially be explained by the role of 
environmental factors or additional modifying genes influencing 
disease manifestations27. A number of relatives have been identi-
fied through cascade screening but are currently asymptomatic or 
have no evidence of renal impairment.
Family F
A 45 year old female presented with proteinuria and progres-
sive CKD but then developed cardiomyopathy. She had initially 
undergone a renal biopsy which reported findings consistent 
with focal segmental glomerular sclerosis (FSGS) however on 
review, the electron microscopy was found to have evidence 
of podocyte vacuolation in keeping with a diagnosis of Fabry 
disease. Mutation analysis confirmed a pathogenic GLA mutation 
p.Arg227*. A number of her relatives have been diagnosed with 
the same genetic mutation following cascade screening however 
they are currently asymptomatic with no evidence of renal 
involvement.
Family G
A 23 year old male presented to renal services with haematu-
ria, proteinuria and progressive CKD. He had classical features 
of Fabry disease including angiokeratoma and LVH. Genetic 
testing confirmed a p.Arg112Cys GLA mutation. Enzyme 
replacement therapy was commenced. Unfortunately, he had a 
progressive decline in renal function resulting in ESRD at the age 
of 33 years of age. He was treated with haemodialysis and renal 
transplantation. He was troubled with significant acroparasthesia. 
He died aged 41 years. Family screening confirmed that his mother 
and sister were carriers of the p.Arg112Cys variant. His mother 
lived to 77 years of age and died of congestive cardiac failure. His 
sister, aged 51 years has an absence of haematuria and proteinuria, 
with preserved renal function.
Family H
A 32 year old male was referred to renal services with a finding of 
elevated serum creatinine and reduced eGFR (45mL/min/1.73m2) 
and was also noted to have angiokeratoma. He underwent a renal 
biopsy which had electron microscopy findings consistent with 
a diagnosis of Fabry disease. He suffered with mild neuropathic 
pain but had no evidence of cardiac involvement. Mutational analy-
sis of GLA revealed a nonsense mutation c.679C>T, p.Arg227*.
His brother was seen the following year aged 22 and was noted 
to have slightly reduced renal function (eGFR 79mL/min/1.73m2) 
with no evidence of microalbuminuria but with evidence of left 
ventricular diastolic dysfunction on echocardiogram. Both brothers 
have been commenced on ERT and six other family members have 
been identified through cascade genetic screening.
Discussion
Inherited renal disease is the fifth most common cause of 
ESRD28. It is vital that a detailed family history of renal and 
extra-renal phenotypes is taken for any new patient presenting 
to renal services, whether the presentation is with hypertension, 
proteinuria or CKD. Only by doing this will the practitioner be 
able to piece together the often subtle clues that the patient may 
have an inherited disorder. If the family pedigree suggests or is 
compatible with X-linked inheritance (i.e. no evidence of male 
to male transmission) then Fabry disease should always be con-
sidered. Similarly the diagnosis should be considered in male 
patients with renal impairment and a finding of parapelvic cysts on 
renal ultrasound11 as in the case of Family C. The European 
Best practice Group also recommend screening of any males 
under the age of 50 with unexplained CKD and to consider 
screening in females of any age19.
Many of the manifestations of Fabry disease are non-specific 
and can occur in other systemic disorders such as diabetes and 
hypertension. As a result of this and a highly variable phenotype 
there is often a significant lag time between presentation to serv-
ices and a diagnosis of Fabry disease. Females and atypically 
presenting males may only have hypertension or mild pheno-
types and it may be difficult to recognize a pattern of inherited 
disease. Family D demonstrates how it may be helpful to revisit 
the family history of a patient with ESRD of unknown cause 
and consider Fabry disease as a potential diagnosis.
Renal biopsy, or as in the case of the patient in Family E, 
examination of renal tissue from nephrectomy, can often be help-
ful making the diagnosis. A small number of patients are iden-
tified co-incidentally through renal biopsy for investigation 
of CKD or proteinuria without any significant family history and 
when the diagnosis has not previously been considered. Screen-
ing for levels of alpha-galactosidase in at risk populations pro-
vides a non-invasive method of identifying patients. Similarly 
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cascade genetic testing rapidly identifies affected family members 
in the absence of symptoms or clinical manifestations; potentially 
allowing treatment to be commenced earlier and prevention of 
disease progression.
Conclusion
The pedigrees and disease spectrum we have described 
demonstrate the significant variation in phenotype, even amongst 
family members who have been confirmed to have the same 
genetic mutation. This along with variation in disease phenotype, 
including the existence of atypical variants of Fabry Disease, 
means that there is often a significant delay before patients 
receive a diagnosis and are therefore able to start ERT and other 
protective treatments. The importance of a high index of clini-
cal suspicion of Fabry disease in patients with unexplained 
CKD and the determination of a full family history cannot be 
stressed enough. With the advent of both dry blood spot alpha- 
galactosidase testing and molecular genetic screening the speed 
and ability to detect affected family members has been signifi-
cantly improved. This allows a precise diagnosis to be made and 
for patients to be commenced on ERT early in their 
disease course with the hope of preventing worsening of symptoms 
and organ damage.
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